d'Asseler Y M, Koole M, Lemahieu I, Achten E, Boon P, De Deyn P P, Dierckx R A
Division of Nuclear Medicine, University Hospital of Gent, Belgium.
Acta Neurol Belg. 1997 Sep;97(3):154-62.
Recent and future evolutions in neuroSPECT apply to radiopharmaceuticals techniques and the synergistic use of different imaging modalities in the work-up of neurological disorders. The introduction of Technetium labelled perfusion tracers, which could pass the intact blood-brain barrier, together with the implementation of the tomographic principle, by making the conventional gamma camera rotating, enabled estimation of regional cerebral blood flow and indirectly of local brain metabolism. In addition at present Thallium-201 and Tc-99m sestaMIBI allow functional detection of viable tumor tissue, without interference from previous surgery or radiotherapy as seen using CT-scan or MRI. In neurology this has led to the recognition of SPECT by the American Academy of Neurology (Therapeutics and technology subcommittee) as an established or promising tool in major neurological disorders such as dementia, stroke and epilepsy, while other domains such as brain oncology are considered investigational. With regard to radiopharmaceuticals, recent evolutions mainly include the development of mostly Iodine-123 labelled receptor ligands, some of which are already commercially available. For instrumentation advances consist e.g. of multidetector systems equipped with fanbeam collimators, attenuation and scatter correction or coincidence detection. Given the present role for nuclear neurology it may be expected that these additional radiopharmaceutical and technical innovations will continue to stimulate the development of SPECT of the brain. The synergistic use of several imaging techniques such as CT, (functional) MRI, source imaging, SPECT and PET represents a multimodal holistic approach to probe cerebral functions for research and clinical purposes. Clinical indications, in which this synergistic use is illustrated include e.g. support of the clinical diagnosis of dementia of the Alzheimer type, presurgical ictal detection of seizure focus, detection of acute ischemia and differential diagnosis between radiation necrosis and brain tumor recurrence. The synergistic use of imaging modalities, optimally applied using image fusion, allows to overcome the intrinsic limitations and to enhance the specific advantages of the different approaches as it leads to increased precision and accuracy, as well for spatial anatomofunctional correlation as for quantification.
神经单光子发射计算机断层扫描(NeuroSPECT)的近期及未来发展涉及放射性药物技术,以及在神经系统疾病检查中不同成像模式的协同应用。锝标记灌注示踪剂的引入,这种示踪剂能够透过完整的血脑屏障,再加上断层扫描原理的应用,通过使传统伽马相机旋转,实现了对局部脑血流的估计,并间接估计局部脑代谢。此外,目前铊-201和锝-99m甲氧基异丁基异腈能够对存活的肿瘤组织进行功能检测,不会受到如CT扫描或MRI所见的先前手术或放疗的干扰。在神经病学领域,这使得美国神经病学学会(治疗与技术小组委员会)认可SPECT为痴呆、中风和癫痫等主要神经系统疾病的既定或有前景的工具,而脑肿瘤学等其他领域则被视为仍在研究中。关于放射性药物,近期的发展主要包括大多是碘-123标记的受体配体的开发,其中一些已经商业化。仪器方面的进展例如包括配备扇形束准直器、衰减和散射校正或符合检测的多探测器系统。鉴于核神经病学目前的作用,可以预期这些额外的放射性药物和技术创新将继续推动脑SPECT的发展。几种成像技术如CT、(功能)MRI、源成像、SPECT和PET的协同应用代表了一种多模式整体方法,用于研究和临床目的探测脑功能。这种协同应用得到体现的临床适应症包括例如支持阿尔茨海默型痴呆的临床诊断、癫痫发作灶的术前发作期检测、急性缺血的检测以及放射性坏死与脑肿瘤复发之间的鉴别诊断。成像模式的协同应用,通过图像融合实现最佳应用,能够克服内在局限性并增强不同方法的特定优势,因为它提高了精度和准确性,无论是对于空间解剖功能相关性还是定量分析。